Literature DB >> 27775994

The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results.

Kerim Sonmezoglu1, Betul Vatankulu, Tugrul Elverdi, Resit Akyel, Melih E Erkan, Metin Halac, Meltem Ocak, Emre Demirci, Yildiz Aydin.   

Abstract

OBJECTIVE: In this observational pilot study, we aimed to evaluate the role of gallium-68-labelled DOTA-TATE (Ga-TATE) PET/computed tomography (CT) scanning in patients with multiple myeloma (MM), considering previous promising results obtained from conventional somatostatin receptor scintigraphy with In pentetreotide.
MATERIALS AND METHODS: Twenty-one patients with a diagnosis of MM were prospectively included in this study: eight patients were referred for initial staging and 13 patients for restaging purpose. Both fluorine-18 fluorodeoxyglucose (F-FDG) and TATE PET/CT scanning were performed in all patients.
RESULTS: All patients had one or more PET-positive lesion on either F-FDG or TATE scans. Six patients had an additional diffusely increased bone marrow activity on F-FDG scans, five of whom also had a concordant bone marrow appearance on TATE scans. Each PET set (either F-FDG or TATE) was positive in 19 patients. There was a discordant result in four (19%) patients between F-FDG and TATE scans. F-FDG scans showed 112 lesions (86 TATE-positive; 26 TATE-negative) in 19 patients, whereas TATE scans showed 108 lesions (86 F-FDG-positive; 22 F-FDG-negative) in 19 patients. No significant difference was found between the two modalities in terms of lesion numbers detected (P=0.67). However, the presence of diffuse bone marrow uptake of TATE seems to be a predicting factor for the overall survival (P=0.033, hazard ratio: 15.2 and 95% confidence interval: 1.2-185.5).
CONCLUSION: TATE PET/CT seems to be an alternative imaging modality and may play a complementary role in MM management, at least by providing a different pathobiological insight into the disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27775994     DOI: 10.1097/MNM.0000000000000610

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

Review 1.  Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.

Authors:  Rasmus Helgebostad; Mona-Elisabeth Revheim; Kjersti Johnsrud; Kristine Amlie; Abass Alavi; James Patrick Connelly
Journal:  Diagnostics (Basel)       Date:  2022-02-18

Review 2.  Recent developments on the application of molecular probes in multiple myeloma: Beyond [18F]FDG.

Authors:  Shaojuan Zhang; Jingjie Shang; Weijian Ye; Tianming Zhao; Hao Xu; Hui Zeng; Lu Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-08-26

3.  Comparison of 68Ga-DOTANOC with 18F-FDG using PET/MRI imaging in patients with pulmonary tuberculosis.

Authors:  Claire M Naftalin; Francesca Leek; James T P D Hallinan; Lih Kin Khor; John J Totman; Jing Wang; Yee Tang Wang; Nicholas I Paton
Journal:  Sci Rep       Date:  2020-08-28       Impact factor: 4.379

4.  Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma.

Authors:  Maria E S Takahashi; Camila Mosci; Edna M Souza; Sérgio Q Brunetto; Elba Etchebehere; Allan O Santos; Mariana R Camacho; Eliana Miranda; Mariana C L Lima; Barbara J Amorim; Carmino de Souza; Fernando V Pericole; Irene Lorand-Metze; Celso D Ramos
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

Review 5.  Metabolic Volume Measurements in Multiple Myeloma.

Authors:  Maria Emilia Seren Takahashi; Irene Lorand-Metze; Carmino Antonio de Souza; Claudio Tinoco Mesquita; Fernando Amorim Fernandes; José Barreto Campello Carvalheira; Celso Dario Ramos
Journal:  Metabolites       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.